A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.
Part of paid clinical trials in Sacramento, California.
- Sponsor
- AstraZeneca
- Study ID
- NCT04495179
- Phase
- PHASE2
- Status
- Completed
Conditions
- Progressive Metastatic Castrate-Resistant Prostate Cancer
Eligibility Criteria
- Sex
- MALE
- Age
- 18 Years - 150 Years
- Healthy Volunteers
- Not accepted
Interventions
- AZD4635 — DRUGSubjects will receive AZD4635 orally daily
- Durvalumab — DRUGSubjects will receive intravenous durvalumab every 4 weeks for Arm A and every 3 weeks for Arm B.
- Cabazitaxel — DRUGSubjects will receive intravenous cabazitaxel every 3 weeks
Study Details
This is a Phase II, international, open-label, two-arm, non-randomised study of AZD4635 in participants with metastatic castration-resistant prostate cancer (mCRPC).
Key Dates
- Start date
- Aug 4, 2020
- Status verified
- Jul 2023
- Primary completion
- Nov 1, 2021
- Completion
- Aug 8, 2022
Study Design
- Enrollment
- 30 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm A: AZD4635 + durvalumabAZD4635 plus durvalumab (Arm A) will consist of participants with mCRPC previously treated with one or more approved NHAs (eg, abiraterone acetate, enzalutamide, apalutamide and/or darolutamide), and one or more taxanes, or participants who are taxane ineligible.
- Experimental: Arm B: AZD4635 + durvalumab + cabazitaxelAZD4635 plus durvalumab plus cabazitaxel (Arm B) will consist of participants with mCRPC previously treated with docetaxel and one prior NHA (either abiraterone acetate or enzalutamide but not both (prior apalutamide is not allowed in Arm B).
Primary Outcome Measure
Radiographic Progression Free Survival (rPFS) in Each Arm Separately to Determine the Efficacy of AZD4635 Plus Durvalumab and of AZD4635 Plus Durvalumab Plus Cabazitaxel in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) [ Time Frame: From first dose to first documented progression or death from any cause (whichever comes first) (approximately 1 year) ]
Locations (5)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Research Site | Sacramento | California | 95817 | - |
| Research Site | Tampa | Florida | 33612 | - |
| Research Site | Atlanta | Georgia | 30318 | - |
| Research Site | St Louis | Missouri | 63110 | - |
| Research Site | Winston-Salem | North Carolina | 27157 | - |